CN104189897A - 一种树突状细胞高效负载抗原的制备方法 - Google Patents
一种树突状细胞高效负载抗原的制备方法 Download PDFInfo
- Publication number
- CN104189897A CN104189897A CN201410216790.7A CN201410216790A CN104189897A CN 104189897 A CN104189897 A CN 104189897A CN 201410216790 A CN201410216790 A CN 201410216790A CN 104189897 A CN104189897 A CN 104189897A
- Authority
- CN
- China
- Prior art keywords
- antigen
- cell
- liposome
- mannose
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 160
- 102000036639 antigens Human genes 0.000 title claims abstract description 160
- 239000000427 antigen Substances 0.000 title claims abstract description 142
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 238000011068 loading method Methods 0.000 title abstract description 6
- 239000002502 liposome Substances 0.000 claims abstract description 80
- 239000006143 cell culture medium Substances 0.000 claims abstract description 15
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 11
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 11
- 125000002091 cationic group Chemical group 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 58
- 150000003904 phospholipids Chemical class 0.000 claims description 57
- 238000001212 derivatisation Methods 0.000 claims description 38
- 229920000151 polyglycol Polymers 0.000 claims description 38
- 239000010695 polyglycol Substances 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- -1 cationic lipid Chemical class 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 239000010409 thin film Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 150000008146 mannosides Chemical class 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 239000013592 cell lysate Substances 0.000 claims description 6
- 102000000763 Survivin Human genes 0.000 claims description 5
- 108010002687 Survivin Proteins 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 239000007640 basal medium Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 3
- ZCUUARXDXQQWDC-XFQVDRJFSA-N CN(C)CCC1([C@@H]([C@]2(CC[C@@H]3[C@]4(CC[C@@H](CC4=CC[C@H]3[C@@H]2C1)O)C)C)[C@H](C)CCCC(C)C)C(N)=O Chemical compound CN(C)CCC1([C@@H]([C@]2(CC[C@@H]3[C@]4(CC[C@@H](CC4=CC[C@H]3[C@@H]2C1)O)C)C)[C@H](C)CCCC(C)C)C(N)=O ZCUUARXDXQQWDC-XFQVDRJFSA-N 0.000 claims description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 claims description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 11
- 238000012258 culturing Methods 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 17
- 239000013598 vector Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 229940029030 dendritic cell vaccine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 208000017815 Dendritic cell tumor Diseases 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010031099 Mannose Receptor Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- MIAKOEWBCMPCQR-GCHJQGSQSA-N p-aminophenyl alpha-D-mannoside Chemical compound C1=CC(N)=CC=C1O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-GCHJQGSQSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- RWANFUZQWINQBY-SJHCENCUSA-N (2r,3r,4s,5r,6r)-2-(hydroxymethyl)-6-(4-isothiocyanatophenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(N=C=S)C=C1 RWANFUZQWINQBY-SJHCENCUSA-N 0.000 description 1
- GGYBJYNRLGNUNZ-NAWOPXAZSA-N (2r,3s,4r,5s,6r)-2-(hydroxymethyl)-6-(2-isothiocyanatophenyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1C1=CC=CC=C1N=C=S GGYBJYNRLGNUNZ-NAWOPXAZSA-N 0.000 description 1
- XDIYNQZUNSSENW-KHYZTKRTSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-KHYZTKRTSA-N 0.000 description 1
- RWANFUZQWINQBY-BNDIWNMDSA-N (2r,3s,4s,5s,6r)-2-(hydroxymethyl)-6-(4-isothiocyanatophenoxy)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(N=C=S)C=C1 RWANFUZQWINQBY-BNDIWNMDSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-GCHJQGSQSA-N (2r,3s,4s,5s,6r)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-GCHJQGSQSA-N 0.000 description 1
- MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 description 1
- XDIYNQZUNSSENW-KZXKDKCNSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O XDIYNQZUNSSENW-KZXKDKCNSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 231100000693 bioaccumulation Toxicity 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410216790.7A CN104189897A (zh) | 2014-05-21 | 2014-05-21 | 一种树突状细胞高效负载抗原的制备方法 |
KR1020167035836A KR20170042512A (ko) | 2014-05-21 | 2015-05-20 | 항원이 로딩된 수지상 세포의 제조 방법 |
RU2016150446A RU2016150446A (ru) | 2014-05-21 | 2015-05-20 | Способ подготовки дендритной клетки наполненой антигеном |
PCT/CN2015/079416 WO2015176662A1 (en) | 2014-05-21 | 2015-05-20 | Method for preparing dendritic cell loaded with antigen |
JP2017513300A JP2017516495A (ja) | 2014-05-21 | 2015-05-20 | 抗原がロードされた樹状細胞の調製方法 |
US15/312,976 US20170296639A1 (en) | 2014-05-21 | 2015-05-20 | Method for preparing dendritic cell loaded with antigen |
EP15796798.5A EP3145538A4 (en) | 2014-05-21 | 2015-05-20 | Method for preparing dendritic cell loaded with antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410216790.7A CN104189897A (zh) | 2014-05-21 | 2014-05-21 | 一种树突状细胞高效负载抗原的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104189897A true CN104189897A (zh) | 2014-12-10 |
Family
ID=52075363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410216790.7A Pending CN104189897A (zh) | 2014-05-21 | 2014-05-21 | 一种树突状细胞高效负载抗原的制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170296639A1 (zh) |
EP (1) | EP3145538A4 (zh) |
JP (1) | JP2017516495A (zh) |
KR (1) | KR20170042512A (zh) |
CN (1) | CN104189897A (zh) |
RU (1) | RU2016150446A (zh) |
WO (1) | WO2015176662A1 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015176662A1 (en) * | 2014-05-21 | 2015-11-26 | Shenzhen Institutes Of Advanced Technology | Method for preparing dendritic cell loaded with antigen |
CN105396140A (zh) * | 2015-12-02 | 2016-03-16 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
CN106119198A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种高效获取dc细胞的方法 |
WO2017083820A1 (en) * | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
CN107335054A (zh) * | 2017-06-30 | 2017-11-10 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
JP2019500021A (ja) * | 2015-11-13 | 2019-01-10 | ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation | 樹状細胞療法においてex vivoでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質 |
CN110522918A (zh) * | 2018-05-25 | 2019-12-03 | 成都瑞博克医药科技有限公司 | 靶向元件及其制备方法和运用 |
CN111744019A (zh) * | 2020-07-01 | 2020-10-09 | 深圳市瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
CN113403276A (zh) * | 2021-06-23 | 2021-09-17 | 河北大学 | 抗体功能化的外泌体制剂及其制备方法和应用 |
CN114099662A (zh) * | 2021-10-27 | 2022-03-01 | 山西协策企业管理咨询有限公司 | 一种单核细胞负载e6e7融合蛋白的疫苗组合物及其制备方法与应用 |
CN114288400A (zh) * | 2022-01-26 | 2022-04-08 | 宁夏医科大学 | 一种改善肿瘤免疫微环境DCs失能的mRNA肿瘤疫苗、制备方法及其应用 |
US11759532B2 (en) | 2019-12-17 | 2023-09-19 | Shenzhen Rhegen Biotechnology Co., Ltd. | mRNA targeting molecule comprising N-acetylgalactosamine binding polypeptide and preparation method therefor |
US11801257B2 (en) | 2008-04-17 | 2023-10-31 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
US11904015B2 (en) | 2012-09-21 | 2024-02-20 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
US11911359B2 (en) | 2007-03-22 | 2024-02-27 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017218533A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
KR101862502B1 (ko) * | 2017-01-02 | 2018-05-29 | 성균관대학교산학협력단 | 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물 |
CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
CN114984198A (zh) * | 2021-02-24 | 2022-09-02 | 中国科学院上海药物研究所 | 包含肿瘤新生抗原纳米制剂和树突状细胞疫苗的试剂盒及其用途 |
CN115073726B (zh) * | 2022-07-04 | 2023-09-26 | 华中科技大学同济医学院附属协和医院 | 一种靶向m2型巨噬细胞甘露糖受体的超声分子探针及其制备方法与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101690805A (zh) * | 2009-09-30 | 2010-04-07 | 中国人民解放军第四军医大学 | 一种树突状细胞靶向纳米脂质体瘤苗的制备工艺 |
WO2012035557A1 (en) * | 2010-09-14 | 2012-03-22 | Council Of Scientific & Industrial Research | Novel cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof |
CN102973506B (zh) * | 2011-09-05 | 2015-06-03 | 中国科学院深圳先进技术研究院 | 阳离子脂质体及其制备方法 |
CN103013915B (zh) * | 2013-01-09 | 2014-05-28 | 高岱清 | 一种高活性负载抗原的树突状细胞的制备方法 |
CN104189897A (zh) * | 2014-05-21 | 2014-12-10 | 深圳先进技术研究院 | 一种树突状细胞高效负载抗原的制备方法 |
-
2014
- 2014-05-21 CN CN201410216790.7A patent/CN104189897A/zh active Pending
-
2015
- 2015-05-20 JP JP2017513300A patent/JP2017516495A/ja active Pending
- 2015-05-20 KR KR1020167035836A patent/KR20170042512A/ko not_active Application Discontinuation
- 2015-05-20 RU RU2016150446A patent/RU2016150446A/ru not_active Application Discontinuation
- 2015-05-20 EP EP15796798.5A patent/EP3145538A4/en not_active Ceased
- 2015-05-20 WO PCT/CN2015/079416 patent/WO2015176662A1/en active Application Filing
- 2015-05-20 US US15/312,976 patent/US20170296639A1/en not_active Abandoned
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11911359B2 (en) | 2007-03-22 | 2024-02-27 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US11801257B2 (en) | 2008-04-17 | 2023-10-31 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
US11911465B2 (en) | 2012-09-21 | 2024-02-27 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
US11904015B2 (en) | 2012-09-21 | 2024-02-20 | Pds Biotechnology Corporation | Vaccine compositions and methods of use |
WO2015176662A1 (en) * | 2014-05-21 | 2015-11-26 | Shenzhen Institutes Of Advanced Technology | Method for preparing dendritic cell loaded with antigen |
WO2017083820A1 (en) * | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
JP2019500021A (ja) * | 2015-11-13 | 2019-01-10 | ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation | 樹状細胞療法においてex vivoでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質 |
EP3374496A4 (en) * | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY |
EP4092112A1 (en) * | 2015-11-13 | 2022-11-23 | PDS Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
AU2016354590B2 (en) * | 2015-11-13 | 2023-11-23 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
JP2022036961A (ja) * | 2015-11-13 | 2022-03-08 | ピーディーエス バイオテクノロジー コーポレイション | 樹状細胞療法においてex vivoでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質 |
US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US11638753B2 (en) | 2015-11-13 | 2023-05-02 | PDS Biotechnology Corporalion | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
CN105396140B (zh) * | 2015-12-02 | 2019-07-02 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
CN105396140A (zh) * | 2015-12-02 | 2016-03-16 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
CN106119198A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种高效获取dc细胞的方法 |
CN107335054B (zh) * | 2017-06-30 | 2021-01-15 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
CN107335054A (zh) * | 2017-06-30 | 2017-11-10 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
CN112292154A (zh) * | 2018-05-25 | 2021-01-29 | 成都瑞博克医药科技有限公司 | 甘露糖靶向的纳米制剂及其制备和应用 |
CN112292154B (zh) * | 2018-05-25 | 2024-03-12 | 成都瑞博克医药科技有限公司 | 甘露糖靶向的纳米制剂及其制备和应用 |
CN110522917A (zh) * | 2018-05-25 | 2019-12-03 | 成都瑞博克医药科技有限公司 | 一种甘露糖修饰的靶向纳米制剂 |
CN110522919A (zh) * | 2018-05-25 | 2019-12-03 | 成都瑞博克医药科技有限公司 | 甘露糖受体靶向的组合物、药物及其制备方法和应用 |
CN110522918A (zh) * | 2018-05-25 | 2019-12-03 | 成都瑞博克医药科技有限公司 | 靶向元件及其制备方法和运用 |
CN110522919B (zh) * | 2018-05-25 | 2023-03-07 | 成都瑞博克医药科技有限公司 | 甘露糖受体靶向的组合物、药物及其制备方法和应用 |
CN110522918B (zh) * | 2018-05-25 | 2023-04-07 | 成都瑞博克医药科技有限公司 | 靶向元件及其制备方法和运用 |
US11759532B2 (en) | 2019-12-17 | 2023-09-19 | Shenzhen Rhegen Biotechnology Co., Ltd. | mRNA targeting molecule comprising N-acetylgalactosamine binding polypeptide and preparation method therefor |
US11707528B2 (en) | 2020-07-01 | 2023-07-25 | Shenzhen Rhegen Biotechnology Co., Ltd. | Mannose-based mRNA targeted delivery system and use thereof |
WO2022000884A1 (zh) * | 2020-07-01 | 2022-01-06 | 深圳市瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
CN111744019A (zh) * | 2020-07-01 | 2020-10-09 | 深圳市瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
CN113403276A (zh) * | 2021-06-23 | 2021-09-17 | 河北大学 | 抗体功能化的外泌体制剂及其制备方法和应用 |
CN114099662A (zh) * | 2021-10-27 | 2022-03-01 | 山西协策企业管理咨询有限公司 | 一种单核细胞负载e6e7融合蛋白的疫苗组合物及其制备方法与应用 |
CN114288400A (zh) * | 2022-01-26 | 2022-04-08 | 宁夏医科大学 | 一种改善肿瘤免疫微环境DCs失能的mRNA肿瘤疫苗、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3145538A4 (en) | 2017-12-06 |
KR20170042512A (ko) | 2017-04-19 |
US20170296639A1 (en) | 2017-10-19 |
WO2015176662A1 (en) | 2015-11-26 |
JP2017516495A (ja) | 2017-06-22 |
RU2016150446A (ru) | 2018-06-21 |
EP3145538A1 (en) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189897A (zh) | 一种树突状细胞高效负载抗原的制备方法 | |
Zhang et al. | Nanovaccines for cancer immunotherapy | |
Guan et al. | Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase | |
Persano et al. | Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination | |
Qin et al. | Development of a cancer vaccine using in vivo click‐chemistry‐mediated active lymph node accumulation for improved immunotherapy | |
Li et al. | Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy | |
Varypataki et al. | Cationic liposomes loaded with a synthetic long peptide and poly (I: C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity | |
Yuba et al. | A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy | |
Mockey et al. | mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes | |
EP3573656B1 (en) | Core/shell structure platform for immunotherapy | |
Shariat et al. | P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer | |
WO2019001339A1 (zh) | 一种新型的肿瘤疫苗及其用途 | |
Liu et al. | An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice | |
US20200384104A1 (en) | Structure-Function Relationships in the Development of Immunotherapeutic Agents | |
Yang et al. | Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice | |
Shi et al. | Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy | |
Su et al. | Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy | |
CN113476598A (zh) | 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用 | |
Shen et al. | A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity | |
Yan et al. | Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles | |
He et al. | Clickable amino acid derivative tuned self-assembly of antigen and adjuvant for cancer immunotherapy | |
CN105602903A (zh) | 一种抗肿瘤干细胞抗原oct4特异性ctl及其制备方法 | |
Zamani et al. | Improving potency of Nanoliposomal AE36 peptide vaccine by adding CD4+ T cell helper epitope and MPL in TUBO breast cancer mice model | |
CN116162138A (zh) | 树枝状多肽及其用途 | |
CN105031631A (zh) | 一种HLA-A0201限制性抗Sox2特异性CTL的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HENGRUI YUANZHENG (SHENZHEN) BIOLOGICAL TECHNOLOGY Free format text: FORMER OWNER: SHENZHEN YUANZHENG CELLS MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150907 Address after: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Applicant after: Shenzhen Advanced Technology Research Inst. Applicant after: Henry is the source of biological science and Technology Co Ltd (Shenzhen) Address before: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Applicant before: Shenzhen Advanced Technology Research Inst. Applicant before: SHENZHEN YUANZHENG CELL MEDICAL TECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151104 Address after: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Applicant after: Shenzhen Advanced Technology Research Inst. Applicant after: Henry is the source of biological science and Technology Co Ltd (Shanghai) Address before: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Applicant before: Shenzhen Advanced Technology Research Inst. Applicant before: Henry is the source of biological science and Technology Co Ltd (Shenzhen) |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141210 |
|
RJ01 | Rejection of invention patent application after publication |